Overview

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Status:
Active, not recruiting

Trial end date:
2028-11-27

Target enrollment:

Participant gender:

Summary

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet
Breast International Group
Frontier Science & Technology Research Foundation, Inc.
Merck Sharp & Dohme Corp.
Myriad Genetic Laboratories, Inc.
NRG Oncology

Treatments:

Olaparib